VIVernon M. Ingram

Vernon M. Ingram

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vernon M. Ingram has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Barbara J. Blanchard

    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

    2 shared publications
  • Albert Chen

    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139

    1 shared publication
  • Amy S. Yu

    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

    1 shared publication
  • Anne E. Hiniker

    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

    1 shared publication
  • Connie C. Lu

    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA

    1 shared publication
  • Joshua D. Bond

    Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139

    1 shared publication

Latest Publications

  • Open Access

    Efficient reversal of Alzheimer's disease fibril formation and elimination of neurotoxicity by a small molecule

    by Barbara J. Blanchard, Albert Chen, Leslie M. Rozeboom, Kate A. Stafford, Peter Weigele, Vernon M. Ingram

    The Aβ1-42 peptide that is overproduced in Alzheimer's disease (AD) from a large precursor protein has a normal amino acid sequence but, when liberated, misfolds at neutral pH to form “protofibrils” and fibrils that are rich in β-sheets. We find that these protofibrils or fibrils are toxic to certain neuronal cells that carry Ca-permeant α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. Disrupting the structure of the Aβ1-42 fibrils and protofibrils might lead to the discovery of molecules that would be very useful in the treatment of AD. A high-throughput screen of a library of >3,000 small molecules with known “biological activity” was set up to find compounds that efficiently decrease the β-sheet content of aggregating Aβ1-42. Lead compounds were characterized by using thioflavin T (ThT) as a β-sheet assay. The most effective of six compounds found was 4,5-dianilinophthalimide (DAPH) under the following conditions: DAPH at low micromolar concentrations abolishes or greatly reduces previously existing fully formed Aβ1-42 fibrils, producing instead amorphous materials without fibrils but apparently containing some protofibrils and smaller forms. Coincubation of the Aβ1-42 peptide with DAPH produces either amorphous materials or empty fields. Coincubation of DAPH and Aβ1-42 greatly reduces the β-sheet content, as measured with ThT fluorescence, and produces a novel fluorescent complex with ThT. When the Aβ1-42 peptide was coincubated with DAPH at very low micromolar concentrations, the neuronal toxicity mentioned above (Ca 2+ influx) was eliminated. Clearly, DAPH is a promising candidate for AD therapy.


  • Elimination of Amyloid β Neurotoxicity

    by Barbara J. Blanchard, Anne E. Hiniker, Connie C. Lu, Yelena Margolin, Amy S. Yu, Vernon M. Ingram

    Aggregation of the Alzheimer amyloid β peptide (Aβ) Ab1-42 forms neurotoxic fibrils. In contact with human neurons the fibrils cause rapid influx of external calcium through AMPA/kainate-channels. If this molecular mechanism reflects in vivo events,


  • Compromised mitochondrial function leads to increased cytosolic calcium and to activation of MAP kinases

    by Yuan Luo, Joshua D. Bond, Vernon M. Ingram

    We have investigated in rat pheochromacytoma PC12 cells the activation of the mitogen-activated protein kinases ERK1 and ERK2 by the mitochondrial uncoupler carbonyl cyanide p -(trifluoromethoxy)phenylhydrazone (FCCP). This treatment slowly decreases ATP levels to 30% of control, whereas the internal calcium level rises very rapidly to 250% of control, derived from internal stores. Tyrosine phosphorylation of ERK1 and ERK2 increases gradually, starting after 5 min of treatment, to reach a maximum at 30 min; the kinase activity reaches 250% when measured after 1 hr of treatment. The drop in ATP levels is slower still. Comparison of the time courses of the rapid rise in cytosolic calcium with the slower increase in ERK1 and ERK2 activation suggests one or more intermediate stages in this pathway. Chelation of cytosolic calcium with dimethyl bis-( o -aminophenoxy)ethane- N , N , N ′, N ′-tetraacetic acid abolished the FCCP-stimulated rise in internal calcium, as well as the tyrosine phosphorylation and the activation of the ERKs. Surprisingly, caffeine, which releases calcium from different internal stores, did not increase the tyrosine phosphorylation and did not activate the ERKs. The FCCP effect on calcium storage may be related to mitochondrial dysfunction in Alzheimer disease, which might result in ineffective buffering of cytosolic calcium that leads to mitogen-activated protein kinase activation and subsequent protein phosphorylations.